As of 5 Nov 2026, Evoq Remedies is loss-making on a trailing 12-month basis, with a net loss of ₹0.24 Cr, so it has no P/E ratio. The share price is ₹1.61, 66% below its 52-week high. Sales grew 7.7% a year over 3 years. It carries very little debt. It is listed on an SME platform with a market cap of ₹4.01 Cr, ranked 11th of 11 Medical Distribution companies by market cap; the shares fell 64% over the past year.
- ₹1.54
- ₹1.61
- ₹1.54
- ₹1.61
- 56K
Health check
- ReturnsBehind
−63.7% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +7.7% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -0.6% vs peer median 9.4%.
- Balance sheetStretched
Practically debt-free, Piotroski 3 of 9.
- Red flags4 to check
Loss-making over the last twelve months.
Small cap
High beta
Key metrics
- Market cap
- ₹4.01 Cr
- Small cap
- P/E
- n/a
- Industry 36.7
- Price to book
- 0.08
- Peers 2.10
- Dividend yield
- 0.00%
- ROE
- −0.5%
- Peers 8.0%
- ROCE
- −0.6%
- Peers 9.4%
- Debt to equity
- 0.00
- Debt ₹0.07 Cr
- EPS (TTM)
- −₹0.10
- OPM (TTM)
- −174.8%
- Net margin −0.9%
- Sales growth
- −98.7%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.15
- EV/EBITDA −17.1
Strengths and risks
Strengths
- Practically debt-free.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −0.5%.
- Quarterly sales down 98.7% on a year ago.
- 66% below its 52-week high.
About Evoq Remedies
Evoq Remedies Limited engages in the pharmaceutical business in India. The company trades in and acts as a commission agent for pharmaceutical products. It also manufactures, distributes, and exports commercial grade, refined, pale pressed grade, and first pressed degummed castor oils; castor oil and de oil cakes; and high protein castor meals. Evoq Remedies Limited was incorporated in 2010 and is based in Ahmedabad, India.
- Headquarters
- Ahmedabad
- Sector
- Healthcare
- ISIN
- INE0JVD01011
- Website
- evoqremedies.com
Price range
- Avg volume (3M)
- 28.9K
- 1-year return
- minus 63.7%
- From 52-week high
- minus 65.7%
Peers · Medical Distribution
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTEROEntero Healthcare Solutions | 1,900.40 | plus 8.34% | 8,279 | 66.0 | 4.90 | 11.3% | 6.7% | 4.4% | 25.7% | – | 0.00% | plus 62.4% |
| APPLAptus Pharma | 465.00 | plus 0.92% | 797 | 100.2 | 28.06 | 29.3% | 31.7% | 15.4% | 49.6% | 187.5% | 0.00% | plus 772.6% |
| ARVAYAArvaya Healthcare | 111.00 | minus 4.31% | 576 | – | – | 1.4% | 2.2% | 0.0% | 193.6% | – | 0.00% | plus 143.1% |
| EVEXIAEvexia Lifecare | 1.46 | minus 3.31% | 274 | 146.0 | 0.67 | 0.3% | 0.3% | 1.6% | 16.6% | 34.5% | 0.00% | minus 15.2% |
| NOVELIXNovelix Pharmaceuticals | 64.66 | minus 4.91% | 184 | 36.7 | 2.93 | 7.4% | 8.0% | 3.1% | 354.8% | – | 0.00% | plus 29.5% |
| AMWILLAmwill Health Care | 44.00 | plus 5.67% | 88 | 7.8 | 1.06 | 15.5% | 14.4% | 14.1% | 14.7% | 54.2% | 2.27% | minus 25.4% |
| CBPLChandra Bhagat Pharma | 55.50 | minus 4.31% | 42 | 13.7 | 1.26 | – | 9.7% | 2.5% | – | – | 0.00% | plus 45.0% |
| EVOQEvoq Remedies | 1.61 | 0.00% | 4 | – | 0.08 | −0.6% | −0.5% | −174.8% | 7.7% | – | 0.00% | minus 63.7% |
| Median of 7 peers | – | −3.31% | 274 | 51.4 | 2.10 | 9.4% | 8.0% | 3.1% | 37.7% | 54.2% | 0.00% | 45.0% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- +7.7%
- ROE
- −0.5%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 20.4 | 4.1 | 11.8 | 25.5 | |
| – | minus 80.1% | +190.1% | +117.0% | |
| 24.1 | 5.6 | 14 | 27 | |
| −3.7 | −1.6 | −2.2 | −1.5 | |
| −18.3% | −39.0% | −19.0% | −5.7% | |
| 6 | 2.3 | 2.4 | 1.3 | |
| 0 | 0 | 0 | 0.1 | |
| – | −0.1 | – | – | |
| 2.3 | 0.6 | 0.1 | −0.3 | |
| 29.1% | 26.0% | 31.2% | 4.4% | |
| 1.6 | 0.5 | 0.1 | −0.2 | |
| – | minus 72.1% | minus 80.5% | minus 372.0% | |
| 1.19 | 0.33 | 0.06 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 13.6 | 13.6 | 24.9 | 24.9 | |
| 11.2 | 11.6 | 19.6 | 19.4 | |
| 9.6 | 4.2 | – | 0.1 | |
| 0.5 | 7.4 | 5.5 | 7.6 | |
| 34.9 | 36.9 | 50 | 51.9 | |
| 0 | 0 | 0.2 | 0.2 | |
| 0.2 | 0.1 | 0.2 | 0 | |
| 34.7 | 36.7 | 49.6 | 51.8 | |
| 34.9 | 36.9 | 50 | 51.9 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −4.3 | 5.3 | −14.6 | −0.3 | |
| −0 | −0 | −0.3 | – | |
| 1.4 | −5.3 | 15 | 0.1 | |
| −2.9 | −0 | 0.1 | −0.2 | |
| −0 | −0 | −0.3 | – | |
| −4.4 | 5.3 | −14.9 | −0.3 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.